JP2022166288A5 - - Google Patents

Download PDF

Info

Publication number
JP2022166288A5
JP2022166288A5 JP2022133225A JP2022133225A JP2022166288A5 JP 2022166288 A5 JP2022166288 A5 JP 2022166288A5 JP 2022133225 A JP2022133225 A JP 2022133225A JP 2022133225 A JP2022133225 A JP 2022133225A JP 2022166288 A5 JP2022166288 A5 JP 2022166288A5
Authority
JP
Japan
Prior art keywords
composition
seq
hiv
vaccine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022133225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022166288A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/013019 external-priority patent/WO2018009246A1/en
Application filed filed Critical
Publication of JP2022166288A publication Critical patent/JP2022166288A/ja
Publication of JP2022166288A5 publication Critical patent/JP2022166288A5/ja
Pending legal-status Critical Current

Links

JP2022133225A 2016-07-08 2022-08-24 Hiv予備免疫化および免疫療法 Pending JP2022166288A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662360185P 2016-07-08 2016-07-08
US62/360,185 2016-07-08
US201662385864P 2016-09-09 2016-09-09
US62/385,864 2016-09-09
US201662409270P 2016-10-17 2016-10-17
US62/409,270 2016-10-17
USPCT/US2017/013019 2017-01-11
PCT/US2017/013019 WO2018009246A1 (en) 2016-07-08 2017-01-11 Hiv pre-immunization and immunotherapy
JP2019500423A JP7162895B2 (ja) 2016-07-08 2017-07-07 Hiv予備免疫化および免疫療法
PCT/US2017/041168 WO2018009847A1 (en) 2016-07-08 2017-07-07 Hiv pre-immunization and immunotherapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019500423A Division JP7162895B2 (ja) 2016-07-08 2017-07-07 Hiv予備免疫化および免疫療法

Publications (2)

Publication Number Publication Date
JP2022166288A JP2022166288A (ja) 2022-11-01
JP2022166288A5 true JP2022166288A5 (enExample) 2023-06-19

Family

ID=60913003

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019500475A Active JP6971492B2 (ja) 2016-07-08 2017-01-11 Hiv予備免疫化および免疫療法
JP2019500423A Active JP7162895B2 (ja) 2016-07-08 2017-07-07 Hiv予備免疫化および免疫療法
JP2021174409A Pending JP2022028677A (ja) 2016-07-08 2021-10-26 Hiv予備免疫化および免疫療法
JP2022133225A Pending JP2022166288A (ja) 2016-07-08 2022-08-24 Hiv予備免疫化および免疫療法
JP2024080081A Pending JP2024099855A (ja) 2016-07-08 2024-05-16 Hiv予備免疫化および免疫療法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2019500475A Active JP6971492B2 (ja) 2016-07-08 2017-01-11 Hiv予備免疫化および免疫療法
JP2019500423A Active JP7162895B2 (ja) 2016-07-08 2017-07-07 Hiv予備免疫化および免疫療法
JP2021174409A Pending JP2022028677A (ja) 2016-07-08 2021-10-26 Hiv予備免疫化および免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024080081A Pending JP2024099855A (ja) 2016-07-08 2024-05-16 Hiv予備免疫化および免疫療法

Country Status (7)

Country Link
US (11) US11911458B2 (enExample)
EP (2) EP3481418A4 (enExample)
JP (5) JP6971492B2 (enExample)
AU (3) AU2017292582C1 (enExample)
CA (1) CA3028982A1 (enExample)
IL (4) IL300730A (enExample)
WO (2) WO2018009246A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
KR20240023703A (ko) * 2017-01-09 2024-02-22 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 예비-면역화 단계가 없는 hiv 면역요법
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
WO2018232359A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
JP2021519069A (ja) * 2018-03-27 2021-08-10 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 遺伝子改変リンパ球の製造方法
WO2019186274A2 (en) 2018-03-30 2019-10-03 University Of Geneva Micro rna expression constructs and uses thereof
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
WO2020227605A2 (en) * 2019-05-08 2020-11-12 The Wistar Institute Of Anatomy And Biology Dna encoded il-36 gamma as an adjuvant
CN112048523A (zh) * 2019-06-05 2020-12-08 南京艾德免疫治疗研究院有限公司 一种常规离心制备高滴度慢病毒载体的方法
WO2021178571A1 (en) * 2020-03-03 2021-09-10 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat hiv
WO2024036217A2 (en) * 2022-08-09 2024-02-15 Fred Hutchinson Cancer Center Immunization strategies to more naturally guide the maturation of antibodies against human immunodeficiency virus (hiv) in hiv-infected subjects
WO2024155830A2 (en) * 2023-01-18 2024-07-25 Fred Hutchinson Cancer Center Viral particle producer cells with landing pad-integrated viral vectors
WO2025050047A1 (en) * 2023-09-01 2025-03-06 American Gene Technologies International Inc. Combination immunotherapy and antiviral treatment

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
CN1115414C (zh) 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 用于基因治疗的病毒载体
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
AU8828598A (en) 1997-08-15 1999-03-08 Rubicon Laboratory, Inc. Retrovirus and viral vectors
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
CA2324225A1 (en) 1998-03-20 1999-09-23 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
US6156514A (en) 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
US6410013B1 (en) 1999-01-25 2002-06-25 Musc Foundation For Research Development Viral vectors for use in monitoring HIV drug resistance
WO2000072886A1 (en) 1999-05-26 2000-12-07 Dana-Farber Cancer Institute, Inc. Episomally replicating lentiviral vectors
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
JP2004505892A (ja) 2000-05-12 2004-02-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒトパピローマウイルス(hpv)−感染細胞の治療
AU2001265187A1 (en) 2000-05-30 2001-12-11 Baylor College Of Medicine Chimeric viral vectors for gene therapy
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US20030119770A1 (en) 2001-08-02 2003-06-26 Zhennan Lai Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors
WO2003015708A2 (en) 2001-08-18 2003-02-27 Myriad Genetics, Inc Composition and method for treating hiv infection
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
WO2003040311A2 (en) 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20070203333A1 (en) 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2005521393A (ja) 2002-03-20 2005-07-21 マサチューセッツ インスティテュート オブ テクノロジー Hiv治療
US20040142416A1 (en) 2002-04-30 2004-07-22 Laipis Philip J. Treatment for phenylketonuria
WO2004037847A2 (en) 2002-05-07 2004-05-06 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
US20040161412A1 (en) 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
ATE443764T1 (de) 2002-11-04 2009-10-15 Univ Massachusetts Allelspezifische rna-interferenz
WO2004053137A2 (en) 2002-12-11 2004-06-24 Cytos Biotechnology Ag Method for protein production
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
US20060246520A1 (en) 2003-05-23 2006-11-02 Institut National De La Sante Et De La Recherche Medicale Gamma delta t cell-mediated therapy
WO2005005644A1 (en) 2003-07-11 2005-01-20 Cytos Biotechnology Ag Gene expression system
US20050019927A1 (en) 2003-07-13 2005-01-27 Markus Hildinger DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
US20050138677A1 (en) 2003-09-16 2005-06-23 Pfister Herbert J. Transgenic animal model for the treatment of skin tumors
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
WO2005033282A2 (en) 2003-10-01 2005-04-14 Pharmacia & Upjohn Company Llc Polyamide compositions and therapeutic methods for treatment of human papilloma virus
US20080039413A1 (en) 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
WO2005051927A1 (ja) 2003-11-26 2005-06-09 Kureha Corporation Hiv-1感染末梢血単核球の刺激培養によるcd4陽性t細胞の培養方法、及びhiv-1の増殖阻害剤
EP1753777B1 (en) 2004-02-25 2014-05-07 Dana-Farber Cancer Institute, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5a
US20060058255A1 (en) 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006023491A2 (en) 2004-08-16 2006-03-02 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
WO2006048215A1 (en) 2004-11-02 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
MX2007010008A (es) 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
CN101160055A (zh) 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
ES2564823T3 (es) 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN
WO2007015122A1 (en) 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer’s disease
US20070032443A1 (en) 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
WO2007133674A2 (en) 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications
WO2007149476A2 (en) 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Assays for non-apoptotic cell death and uses thereof
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2008008719A2 (en) 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene
EP1878440A1 (en) 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
EP2049103A2 (en) 2006-07-26 2009-04-22 Novartis AG Inhibitors of undecaprenyl pyrophosphate synthase
US20080199961A1 (en) 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
ES2639568T3 (es) * 2007-01-23 2017-10-27 Janssen Pharmaceutica Nv Método para diseñar un régimen farmacológico para pacientes infectados con el VIH
CA2682694A1 (en) 2007-04-12 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
US20080293142A1 (en) 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Construction
EP2008656A1 (en) 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
US20110177155A1 (en) * 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
WO2009089568A1 (en) 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
EP2090659A1 (en) 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof
GB0802754D0 (en) 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4
JP2011517409A (ja) * 2008-03-28 2011-06-09 バイレクシス コーポレイション レンチウイルスベースの免疫原性ベクター
GB0810209D0 (en) 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor
BRPI0913852A2 (pt) 2008-06-16 2015-10-20 Polyplus Battery Co Inc células de bateria de ar/lítio aquoso
US8629334B2 (en) 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees
US20110207226A1 (en) 2008-08-20 2011-08-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system
WO2010033722A2 (en) 2008-09-17 2010-03-25 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
CN102369288A (zh) 2008-11-14 2012-03-07 生命技术公司 用于工程化细胞的组合物和方法
EP2191834A1 (en) 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
US20120034197A1 (en) * 2009-04-09 2012-02-09 Stemcyte Inc. Hiv-resistant stem cells and uses thereof
KR20120088542A (ko) 2009-04-13 2012-08-08 아프세스 게엠베하 & 씨오. 카게 종양 치료를 위한 조작된 중간엽 줄기세포 및 이를 사용하는 방법
EP2425001A4 (en) 2009-04-30 2012-11-14 Univ California ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
AU2010274031B2 (en) 2009-07-15 2015-07-16 Csl Behring Gene Therapy, Inc. Dual vector for inhibition of human immunodeficiency virus
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 hiv에 대한 광범위한 t-세포 반응의 생성
WO2011066578A1 (en) 2009-11-30 2011-06-03 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
CN101805750B (zh) 2009-12-29 2011-11-30 浙江大学 法呢基焦磷酸合成酶rna干扰重组慢病毒载体构建及用途
WO2011103417A2 (en) * 2010-02-18 2011-08-25 Emory University Of Technology Transfer Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
WO2011119942A1 (en) 2010-03-25 2011-09-29 Vistagen Therapeutics, Inc. Induction of ips cells using transient episomal vectors
US20130090371A1 (en) 2010-04-20 2013-04-11 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
DK2561078T3 (en) 2010-04-23 2019-01-14 Cold Spring Harbor Laboratory NEW STRUCTURALLY DESIGNED SHRNAs
JP5965392B2 (ja) 2010-05-28 2016-08-03 オックスフォード バイオメディカ (ユーケー) リミテッド 脳へのレンチウイルスベクターの送達
JP5805089B2 (ja) 2010-08-10 2015-11-04 タカラバイオ株式会社 細胞集団の製造方法
WO2012048303A2 (en) 2010-10-07 2012-04-12 Columbia University METHOD FOR TREATING CANCER HARBORING A p53 MUTATION
WO2012061075A2 (en) 2010-10-25 2012-05-10 The Regents Of The University Of California Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
WO2012140127A2 (en) 2011-04-13 2012-10-18 Immunicum Ab Method for priming of t cells
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
CA2856137A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
SG11201404741VA (en) 2012-02-07 2014-09-26 Global Bio Therapeutics Usa Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA2875624A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
US9556433B2 (en) 2012-07-17 2017-01-31 Université De Genève Nucleic acids for down-regulation of gene expression
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
CA2930339A1 (en) 2012-11-13 2014-05-22 Jan Lotvall Delivery of therapeutic agent
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
WO2014117050A2 (en) * 2013-01-26 2014-07-31 Mirimus, Inc. Modified mirna as a scaffold for shrna
CN103184224A (zh) 2013-04-03 2013-07-03 衡阳师范学院 一种抗艾滋病病毒感染的三联miRNA及构建方法
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP3461909A1 (en) 2013-05-21 2019-04-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
CA2954168C (en) 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2015042308A2 (en) * 2013-09-18 2015-03-26 City Of Hope Rna-based hiv inhibitors
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
CA3205555A1 (en) 2014-04-25 2015-10-29 Genethon Treatment of hyperbilirubinemia
IL296691B2 (en) 2014-04-25 2023-11-01 2Seventy Bio Inc MND promoter chimeric antigen receptors
CA2955254A1 (en) 2014-08-29 2016-03-03 Immunomedics, Inc. Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
ES2896401T3 (es) 2014-09-22 2022-02-24 Tanea Medical Ab Proteínas recombinantes exentas de Phe para su uso en el tratamiento de la fenilcetonuria
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2016057980A1 (en) 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
EP3206696A4 (en) 2014-10-14 2018-08-08 Texas Tech University System Multiplexed shrnas and uses thereof
WO2016069521A1 (en) * 2014-10-27 2016-05-06 International Aids Vaccine Initiative Optimized hiv envelope gene and expression thereof
WO2016069716A1 (en) 2014-10-30 2016-05-06 The Scripps Research Institute Compositions and methods comprising tyrosyl-trna synthetases and resveratrol compounds
WO2016186708A1 (en) 2015-05-18 2016-11-24 Calimmune, Inc. Gene therapeutic for the treatment of hiv and uses thereof
GB201509202D0 (en) 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
US20180161455A1 (en) 2015-06-10 2018-06-14 American Gene Technologies International, Inc. Non-integrating viral delivery system and methods of use therof
WO2017007994A1 (en) * 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
US11028369B2 (en) 2015-08-13 2021-06-08 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Induced extended pluripotent stem cells, method of making and using
CN105112370B (zh) 2015-08-25 2019-02-05 杭州优善生物科技有限公司 一种体外刺激外周血γδT细胞高效增殖的方法及其应用
US10738099B2 (en) 2015-09-22 2020-08-11 The Trustees Of The University Of Pennsylvania Method of redirecting T cells to treat HIV infection
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
WO2018025923A1 (ja) 2016-08-03 2018-02-08 国立大学法人鹿児島大学 抗htlv-1剤、htlv-1関連脊髄症(ham/tsp)治療薬
BR112019013576A2 (pt) 2016-12-30 2020-02-04 The Trustees Of The University Of Pennsylvania terapia genica para o tratamento da fenilcetonuria
KR20240023703A (ko) 2017-01-09 2024-02-22 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 예비-면역화 단계가 없는 hiv 면역요법
US12023385B2 (en) 2017-02-08 2024-07-02 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
WO2018232359A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
CA3077355A1 (en) 2017-10-02 2019-04-11 American Gene Technologies International Inc. Vectors with promoter and enhancer combinations for treating phenylketonuria
JP2021519069A (ja) 2018-03-27 2021-08-10 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 遺伝子改変リンパ球の製造方法
KR20210031898A (ko) 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
KR20220068954A (ko) 2019-05-31 2022-05-26 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 최적화된 페닐알라닌 히드록실라아제 발현

Similar Documents

Publication Publication Date Title
JP2022101658A5 (enExample)
JP2019525914A5 (enExample)
US20240091339A1 (en) Pre-immunization and immunotherapy
JP2019527055A5 (enExample)
JP2019509029A5 (enExample)
JP2018524335A5 (enExample)
US20240115604A1 (en) Methods of manufacturing genetically-modified lymphocytes
AU2018205388A1 (en) HIV immunotherapy with no pre-immunization step
EP3319631A1 (en) Hiv pre-immunization and immunotherapy
US20240141374A1 (en) On demand expression of exogenous factors in lymphocytes
JP2023516685A5 (enExample)
JP2021519069A5 (enExample)
Nakayama et al. Importance of the N-glycan in the V3 loop of HIV-1 envelope protein for CXCR-4-but not CCR-5-dependent fusion
Dash et al. Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection
Lori et al. Gene therapy approaches to HIV infection
WO2025064901A2 (en) Hiv vaccination and immunotherapy
WO2025050047A1 (en) Combination immunotherapy and antiviral treatment
CN108148875B (zh) 一种基因编辑系统、表达载体、基因编辑试剂盒及其用途
Tebas et al. Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor
JPH10511400A (ja) 複製障害HIV−1nef欠失変異体を含むヒト免疫不全ウイルスワクチンおよび治療方法
Arteaga Strategies of gene and immune therapy for tumors and viral diseases